Low-profile RNAi player lands on HKEX following modest $50M IPO
A low-profile small interfering RNA player has managed to squeeze in its IPO before the year ends, adding another listing to the Hong Kong stock exchange’s tally.
Sirnaomics is making its HKEX debut with a modest raise of slightly over $50 million, with the potential of adding about $10 million if the over-allotment option is exercised in full.
CEO Patrick Lu founded the biotech all the way back in 2007, setting up an early discovery operation in Gaithersburg, MD after a transition from research at Georgetown into industry — first working for Novartis then co-founding another company called Intradigm. Through it all, he was focused on what he calls nucleic acid drug development.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,700+ biopharma pros reading Endpoints daily — and it's free.